RESUMEN
1. Much evidence in the literature supports the idea that cholecystokinin (CCK) interacts with opioids in pain mechanisms. In this work, we have investigated the supraspinal interactions between enkephalins and CCK, using the hot plate test in mice. 2. Intracerebroventricular (i.c.v.) administration of BDNL (a mixed CCKA/CCKB agonist) induced dose-dependent antinociceptive responses on both paw lick and jump responses. In contrast, using the same test, the i.c.v. injection of BC 264 (a selective CCKB agonist) induced a hyperalgesic effect, which was restricted to paw licking and occurred only at a high dose of 2.5 nmol. 3. In addition, i.c.v. administration of BDNL potentiated the antinociceptive effects of the mixed inhibitor of enkephalin degrading enzymes, RB 101 and of the mu-agonist, DAMGO, while BC 264 reduced these effects. 4. Furthermore, at a dose where it interacts selectively with delta-opioid receptors, the opioid agonist BUBU reversed the hyperalgesic responses of BC 264 (2.5 nmol) but was unable to modify the effects induced by BDNL. 5. Taken together, these results suggest the existence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. These regulatory loops could enhance the antinociceptive effects of morphine allowing the opiate doses used to be reduced and thus, possibly, the side-effects to be minimized.
Asunto(s)
Analgésicos/farmacología , Colecistoquinina/farmacología , Endorfinas/farmacología , Encefalinas/fisiología , Dolor/fisiopatología , Médula Espinal/efectos de los fármacos , Secuencia de Aminoácidos , Animales , Colecistoquinina/análogos & derivados , Colecistoquinina/antagonistas & inhibidores , Colecistoquinina/fisiología , Disulfuros/farmacología , Endorfinas/antagonistas & inhibidores , Encefalina Ala(2)-MeFe(4)-Gli(5) , Encefalinas/farmacología , Inyecciones Intraventriculares , Masculino , Ratones , Datos de Secuencia Molecular , Oligopéptidos/farmacología , Dimensión del Dolor/efectos de los fármacos , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/farmacología , Fenilalanina/análogos & derivados , Fenilalanina/farmacología , Sincalida/análogos & derivados , Sincalida/farmacologíaRESUMEN
Agonists and antagonists selective for the brain-type [cholecystokinin (CCK)-B] and the peripheral-type (CCK-A) CCK receptor were used to localize the site(s) of action at which CCK inhibits food consumption. BC 264, a highly selective CCK-B receptor agonist, did not decrease consumption of a palatable meal when administered either i.p. or into the lateral ventricles of the brain, whereas CCK decreased feeding when administered i.p. at the same doses. CCK decreased feeding when administered i.v.t. at a high dose, 5 micrograms. L-364,718, an antagonist selective for the CCK-A receptor, blocked completely the action of centrally administered CCK, whereas L-365,260, a selective CCK-B receptor antagonist, had no effect on the ability of centrally administered CCK to inhibit feeding. To estimate the quantity of i.v.t. administered CCK which reached the periphery, a tracer of radiolabeled [3H]p-CCK8 ([3H]CCK octapeptide sulfate), combined with unlabeled pCCK8 (5 micrograms) was administered i.c.t. Thirty minutes after administration, intact radiolabeled pCCK8 was extracted from the plasma and measured in the blood in nanomolar concentrations, exceeding the amounts of CCK octapeptide sulfate reported previously to be present in the plasma after a meal. Intraventricularly administered CCK thus appears to reduce feeding in the rat through a mechanism involving a CCK-A receptor subtype in the periphery.
Asunto(s)
Colecistoquinina/farmacología , Ingestión de Alimentos/efectos de los fármacos , Compuestos de Fenilurea , Receptores de Colecistoquinina/fisiología , Animales , Benzodiazepinonas/farmacología , Colecistoquinina/análogos & derivados , Colecistoquinina/antagonistas & inhibidores , Devazepida , Relación Dosis-Respuesta a Droga , Inyecciones Intraperitoneales , Inyecciones Intraventriculares , Masculino , Fragmentos de Péptidos/farmacología , Ratas , Ratas Endogámicas , Receptores de Colecistoquinina/efectos de los fármacos , Sincalida/análogos & derivados , Sincalida/farmacocinética , Sincalida/farmacologíaAsunto(s)
Acetilmuramil-Alanil-Isoglutamina/farmacología , Adyuvantes Inmunológicos , Glutamatos/farmacología , Glicopéptidos/farmacología , Aminoácidos , Animales , Femenino , Cobayas , Técnicas In Vitro , Masculino , Ratones , Proteínas , Bazo/metabolismo , Relación Estructura-Actividad , Timidina/metabolismoRESUMEN
It has been previously reported that N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), which represents the minimal structure that can substitute for mycobacteria in Freund complete adjuvant, activated macrophages in vitro and in vivo. In the present study we show that, in contrast to MDP, the nonadjuvant MDP(DD) stereoisomer has no effect on cytostatic activity of thioglycolate-induced macrophages as measured by uptake of [3H]thymidine. However, surprisingly, after conjugation to an inert carrier, multi-poly(DL-alanyl)-poly(L-lysine), this compound activates macrophages in vitro and becomes at least as effective as MDP. It has also been shown in other studies that after conjugation MDP(DD) remained devoid of antigenicity and of adjuvant activity although such a conjugate could increase resistance to infection. It, therefore, appears that there exists no correlation between the structure required for adjuvant activity and the structure required for macrophage activation or for enhancement of nonspecific immunity.